Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Afuzam is an oral combination medication developed by Bernard Biotech, pairing the macrolide antibiotic azithromycin with the probiotic lactic acid bacillus. Azithromycin exerts its antibacterial effect by binding to the 50S ribosomal subunit of the bacterial ribosome, which prevents the translocation of peptides and inhibits RNA-dependent protein synthesis. The lactic acid bacillus component is a live biotherapeutic intended to replenish beneficial intestinal bacteria, thereby preventing or treating antibiotic-associated diarrhea and maintaining a balanced gut microbiome during antibiotic therapy. It is indicated for the treatment of various respiratory, skin, and soft tissue infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azithromycin + lactic acid bacillus.